Axsome to Present on Cognitive and Wake-Promoting Effects of Solriamfetol
Axsome Therapeutics Inc will present new data on solriamfetol’s impact on cognition and sleep at the American Academy of Neurology 2024 annual meeting.
Tag: Narcolepsy
All
Latest
All
Latest
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial
Axsome Therapeutics announced topline trial results, which show AXS-12 significantly improves key narcolepsy symptoms, including cataplexy and cognitive function.
All
Latest
Three Hospitalized After Inappropriate Use of Narcolepsy Drugs
The men experienced serious skin reactions and mouth ulcers after taking drugs indicated for narcolepsy. They had been hoping for cognitive enhancement.
FDA Grants Priority Review for Wakix in Pediatric Narcolepsy Treatment
The FDA has granted priority review to Harmony Biosciences’ supplemental New Drug Application for Wakix for treating excessive daytime sleepiness or cataplexy in children aged 6 and older with narcolepsy.
Read More
Alkermes Readies for Phase 2 Trial of Orexin-2 Receptor Agonist for Narcolepsy
Alkermes plans to initiate phase 2 trials for its orexin-2 receptor agonist, ALKS 2680, aimed at treating narcolepsy within the first half of the year.
Read More
Takeda’s Oral Orexin Agonist to Enter Phase 3 Trials in Narcolepsy Type 1
Takeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Read More
How to Select the Most Suitable Pharmacotherapy for Type 1 Narcolepsy Patients
Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read More
Harmony Reports Growth in Patient Use of Narcolepsy Drug Wakix
Harmony Biosciences announced an increase in the usage of its narcolepsy drug Wakix (pitolisant) during the fourth quarter.
Read More
Lumryz Gains Ground in Narcolepsy Treatment, Reports Avadel
Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.
Read More
Axsome Eyes Phase 3 Trial Milestones for Sleep Disorder Drug Candidates in 2024
Axsome Therapeutics details anticipated milestones for investigational drugs for narcolepsy and excessive daytime sleepiness associated with shift work disorder.
Read More
Patients With Narcolepsy Face a Dual Nightmare of Medication Shortages and Stigma
The ongoing Adderall shortage is creating widespread difficulties for narcolepsy patients, disrupting treatment and daily life across the US.
Read More
The Study of Dreams: Scientists Uncover New Communication Channels With Dreamers
New research suggests it’s possible to interact and communicate with people during sleep, potentially across various sleep stages.
Read More
NLS Pharmaceutics, Whose Narcolepsy Drug Candidate Is In Clinical Trials, Recaps 2023
In a letter to shareholders, the CEO of Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd recapped the company’s progress and pitfalls for 2023.
Read More
NLS Pharmaceutics Acquires Rights to Aexon Labs’ Orexin Agonists
The option agreement grants NLS Pharmaceutics the exclusive option to in-license all of Aexon Labs’ assets for the potential treatment of narcolepsy and other neurodegenerative disorders.
Read More
Jazz Pauses Orexin Agonist Trial After Reports of ‘Visual Disturbances’
Jazz Pharmaceuticals is pausing its phase 1 clinical trial investigating JZP441, an oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy and other sleep disorders, after reports of adverse effects.
Read More
NLS Out-Licenses Mazindol As It Explores Strategic Alternatives
NLS Pharmaceutics is exploring strategic alternatives, including the out-licensing of its key asset Mazindol, to maximize shareholder value.
Read More
Centessa Provides Q3 Updates for Investigational Narcolepsy Drug ORX750
Centessa Pharmaceuticals announced third-quarter updates for its narcolepsy drug candidate, ORX750, an orexin receptor 2 agonist.
Read More
Xywav Maintains Upward Trajectory in Narcolepsy and Idiopathic Hypersomnia Treatment
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
Read More